Dignify Therapeutics Announces the Issuance of US Patent No. 10,086,034 for treatment of voiding dysfunction
RESEARCH TRIANGLE PARK, NC (RTP) – October 18, 2017 - Dignify Therapeutics, LLC, a leading developer of therapies for bladder and bowel dysfunction, announces the issuance of US Patent No. 10,086,034, which relates to pharmacological methods of inducing urination and defecation.
Dr. Karl Thor, Chief Scientific Officer and patent co-inventor stated “This is an important accomplishment for the company as we expand our portfolio of treatments for individuals with voiding disorders. This patent helps solidify our mission to restore voluntary “on demand” bladder and bowel voiding to those patients that are unable to voluntarily void or voluntarily control bladder or bowel activity.” Dr. Aura Kullmann is also a co-inventor.
Many individuals with spinal cord injury, multiple sclerosis, spina bifida, Parkinson’s disease, diabetes as well as many elderly people cannot completely or efficiently empty their bladder or bowel without the assistance of bladder catheters or bowel programs. Dignify’s US Patent No. 10,086,034 describes a method of drug-induced voiding that could potentially replace bladder catheters and bowel programs, thus improving the standard of care and quality of life for individuals that experience voiding dysfunction.
About Dignify Therapeutics LLC
Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, treatments for bladder and bowel voiding dysfunction. The Company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA and the One NC Small Business Program. Dignify, a member of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in Research Triangle Park, North Carolina.
Ed Burgard, President
P.O. Box 13169 – 2 Davis Drive
Research Triangle Park, NC 27709